Anti-TSLP Antibody Dosing Intervals for Asthma Exacerbation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma, such as tezepelumab, have high dosing frequencies and burdens, affecting patient compliance and efficacy in reducing asthma exacerbations and severity.
Innovation Solution
A method using a low-dose, anti-TSLP antibody or antigen-binding fragment administered at extended intervals (e.g., every 12-24 weeks) to treat asthma, potentially combined with background therapies, reducing dosing frequency and improving compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current asthma treatments like tezepelumab are used with approved dosing regimens, then asthma exacerbation reduction is achieved, but dosing frequency is high and treatment burden is heavy
Solution Approach 1:
The patent applies periodic action by establishing extended dosing intervals for anti-TSLP antibodies, moving from monthly or quarterly dosing to dosing intervals of 12-24 weeks or longer. This periodic administration pattern maintains therapeutic efficacy while significantly reducing the frequency of patient visits and injections, thereby resolving the contradiction between reliable asthma control and ease of operation.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the dosing interval parameter from the originally approved shorter intervals to extended intervals of 12-24 weeks or more. This parameter adjustment, combined with appropriate dosage selection, maintains the reliability of asthma exacerbation reduction while improving ease of operation by reducing treatment burden.
2Reliability
If dosing frequency is increased to maintain therapeutic effect, then asthma control reliability is improved, but patient compliance deteriorates
Solution Approach 1:
By implementing extended periodic dosing intervals of 12-24 weeks or longer, the patent reduces the number of administrations required to maintain therapeutic effect. This periodic action pattern improves patient compliance by minimizing treatment burden while preserving asthma control reliability through maintained TSLP inhibition.
Solution Approach 2:
The extended dosing interval regimen allows the treatment to effectively serve itself over longer periods, reducing the need for frequent patient interventions. This self-service approach improves compliance by making the treatment regimen more sustainable and less burdensome for patients while maintaining therapeutic reliability.
3Ease of operation
If dosing frequency is reduced to improve compliance, then treatment burden is decreased, but asthma exacerbation reduction efficacy may be compromised
Solution Approach 1:
The patent optimizes the dosing interval parameter to extended ranges of 12-24 weeks or longer, combined with appropriate dosage selection, to maintain sufficient TSLP inhibition levels. This parameter change reduces treatment burden and improves ease of operation while preserving the reliability of asthma exacerbation reduction through sustained therapeutic effect.
Data Source
AI summary
The present disclosure provides a method for treating asthma using a TSLP antibody. Specifically, the present disclosure utilises an antibody against thymic stromal lymphopoietin (TSLP) or an antigen-binding fragment thereof to treat asthma and/or reduce the frequency and/or severity of asthma exacerbations, and/or reduce the annualised asthma exacerbation rate, and/or reduce the subject's ACQ-6 score.